Ascletis Strategy Begins To Reach Fruition In Deal With Alnylam For HCC Candidate
This article was originally published in PharmAsia News
Executive Summary
U.S.-China hybrid Ascletis is in-licensing rights to Phase II-ready RNA-interference program ALN-VSP from Alnylam with an eye on developing a groundbreaking therapy for an underserved indication that hits especially hard in China.
You may also be interested in...
Ascletis Eyes Launch Of China’s First Oral HCV Drug, Possible IPO
Already well-funded Chinese venture Ascletis has completed a large Series B to support the commercialization of effective new oral HCV drugs and progress its pipeline, and has not ruled out the possibility of going public in an IPO.
Ascletis Opens Its $100 Million Wallet - Breaks Ground On China Facility, Sets Sights On In-Licensing
HANGZHOU, China - U.S.-China hybrid Ascletis Inc. is putting some of its $100 million Series A funding to immediate use, breaking ground Oct. 20 on a facility in Zhenjiang Province that will house its China headquarters and R&D center
U.S.-China Hybrid Ascletis Helps Forge Stronger Ties Between China And North Carolina
U.S.-China hybrid Ascletis Inc. has reinforced ties between China and the U.S. under a memorandum of understanding signed July 16 with the Hangzhou Hi-Tech Industry Development Zone in Zhejiang Province, China, and The Hamner Institutes for Health Sciences in Research Triangle Park, North Carolina